• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

UCB immunology





Under the leadership of Ismail Kola back in the day it was growing well. Now that Deval Patel is head of R&D, prepared to be micromanaged as much as a German beancounter in 1919.
 




Oh that’s not a good environment if the CSO gets too busy with the lower levels. Is this micromanagement filtered down to the Immunology R&D side with the middle management too?
 




Oh that’s not a good environment if the CSO gets too busy with the lower levels. Is this micromanagement filtered down to the Immunology R&D side with the middle management too?

Senior Principal scientists who was to execute £30,000 of laboratory experiments needs sign off by Deval Patel. Yep, its bad.